samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Kite, a Gilead Company, Continues to Advance Research With Longest CAR T Cell Therapy Follow-up Data at the 4th European CAR T-cell Meeting

Kite Pharma


• Pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphoma
• Safety management data in relapsed/refractory diffuse large B cell lymphoma


“We are pleased to support the 4th European CAR T-cell Meeting with presentations demonstrating potential long-term survival with CAR T cell therapy in relapsed/refractory diffuse large B cell lymphoma,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “First European presentations of our pivotal head-to-head ZUMA-7 trial and patient-reported outcomes in second-line relapsed/refractory diffuse large B cell lymphoma also support our ongoing commitment to patients with hard-to-treat blood cancers.”

ZUMA-1: Axicabtagene Ciloleucel
Updated overall survival results at five years from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (Yescarta®) in patients with relapsed/refractory diffuse large B cell lymphoma will be presented.

ZUMA-7: Axicabtagene Ciloleucel
The first European presentation of the pivotal Phase 3 ZUMA-7 study primary analysis and patientreported outcomes, evaluating the safety and efficacy of axicabtagene ciloleucel versus current standard of care for second-line therapy in relapsed/refractory diffuse large B cell lymphoma.

Study Name and Abstract Number
Abstract Title
Primary Author

E-Poster and Flash Talk
ZUMA-1 Cohort 6 One-Year
Poster Number: AS-CART-2022-00058
PT02-4 Thurs 10 Feb, 19:29 CET
Prophylactic Corticosteroids with Axicabtagene Ciloleucel (Axi-Cel) in Patients with
Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Olalekan O. Oluwole
ZUMA-7 Elderly Poster Number: AS-CART-2022-00054 PT02-1
Thurs 10 Feb, 19:20 CET
Superiority of Axicabtagene Ciloleucel (Axi-Cel) in SecondLine (2L) Large B-Cell Lymphoma (LBCL) in the Elderly Tom van Meerten
 E-Poster Presentation
ZUMA-1 Five-Year Overall Survival Poster Number: AS-CART-2022-00058
Long-Term (5 Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) Caron A. Jacobson
Real World Evidence: CIBMTR Registry Asian Descent Subset Analysis Poster Number:
AS-CART-2022-00138
Real-world Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-cell Lymphoma (LBCL): Subset Analysis of Patients with Asian Descent Tanya Siddiqi
ZUMA-7 Primary Analysis Poster Number: AS-CART-2022-00055
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma Frederick L. Locke
Health Economics and Outcomes Research: ZUMA-7 Patient Reported Outcomes Poster Number: AS-CART-2022-00057 Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma Mahmoud Elsawy
ZUMA-5 Two-Year Follow-Up Poster Number: AS-CART-2022-00053  Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) Julio Chavez
ZUMA-12 Primary Analysis Poster Number: AS-CART-2022-00049
Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) Julio Chavez/Sattva S. Neelapu

phone (310) 824-9999
web https://www.kitepharma.com/
email 2400 Broadway Santa Monica, CA 90404
 
Print this page
Send to a friend
   
spacer
News and Press Releases

X‑Chem and Excelra’s GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets

LONDON and HYDERABAD, India; Feb. 9, 2022 – A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets.
More info >>


White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement